Skip to Content
PharmaceuticalsPharmaceuticals
  • Correction
  • Open Access

25 February 2026

1 Page

Correction: Pan et al. Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. Pharmaceuticals 2025, 18, 1159

,
,
,
,
,
,
,
,
and
1
Mary & Dick Holland Regenerative Medicine Program, University of Nebraska Medical Center, Omaha, NE 68198, USA
2
Division of Cardiology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA
3
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA
4
Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA

Citation Correction

In the original publication [1], Section “3. Discussion”. Original sentence: “In ovarian cancer models, co-treatment with BMX-001 and PTX significantly reduced the cell viability of CAOV2 cells compared to PTX alone and downregulated the expression of BCL2, NF-κB, and IL-1β [49].”
Original citation for [49] is “Batinic-Haberle, I.; Tovmasyan, A.; Veade, A.; Spasojevic, I.; Reihani, S.; Secord, A. Mn porphyrin/ascorbate sensitizes serous epithelial ovarian cancer to chemotherapy. Free. Radic. Biol. Med. 2018, 128, S74–S75.” It has been correctly replaced with [2].
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

References

  1. Pan, T.; Alimi, O.A.; Liu, B.; Krishnan, M.A.; Kuss, M.; Shi, W.; Krishnamurthy, J.; Dong, J.J.; Oberley-Deegan, R.E.; Duan, B. Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. Pharmaceuticals 2025, 18, 1159. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Spasojevic, I.; da Silva, W.T.A.; Huang, Z.; Duan, W.; Du, L.; Chen, C.; Cao, J.; Zhang, S.; Lee, H.; Lo, G.; et al. Redox-active Mn porphyrin-based clinical candidate, MnTnBuOE-2-PyP5+ (BMX-001) reduces paclitaxel-induced neuropathy, while suppressing ovarian cancer growth. Free Radic. Biol. Med. 2024, 224, S54–S55. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.